Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a niche pharmaceutical distributor like Wellgistics Health Inc. (WGRX) navigates FDA regulations, temperature-controlled logistics, and reimbursement rules isn’t easy. Each 10-K packs dense disclosures about specialty-drug margins, while every 8-K details new wholesaler contracts that can reshape revenue overnight. If you have ever wondered, “Why are Wellgistics Health insider trading Form 4 transactions spiking before a new supplier deal?” you are not alone.
Stock Titan solves the puzzle. Our AI reads every Wellgistics Health quarterly earnings report 10-Q filing the moment it hits EDGAR, then delivers plain-English highlights—cash-flow swings, inventory turns, and segment performance—so you can focus on decisions, not decoding. Need real-time alerts? We ping you the second a Wellgistics Health Form 4 insider transactions real-time notice appears. The platform also answers natural questions such as “Are Wellgistics Health SEC filings explained simply anywhere?” or “What does today’s 8-K mean for cold-chain capacity?”
Beyond summaries, you’ll find deep links to every document type investors care about:
- 10-K & 10-Q: Examine logistics network costs with our Wellgistics Health earnings report filing analysis and Wellgistics Health annual report 10-K simplified.
- Forms 4: Track Wellgistics Health executive stock transactions Form 4 to spot confidence shifts.
- DEF 14A: See the Wellgistics Health proxy statement executive compensation breakdown of distribution-team incentives.
- 8-K: Get Wellgistics Health 8-K material events explained—from new warehouse leases to supply interruptions.
Wellgistics Health, Inc. reported significant operating losses and liquidity strain for the period ending June 30, 2025. The company recorded a net loss of $39.1 million for the six months and $6.67 million for the three months, contributing to an accumulated deficit of $48.86 million. Net cash used in operating activities for the six months was $3.43 million, and the registrant disclosed that these factors raise substantial doubt about its ability to continue as a going concern. The company completed an IPO raising gross proceeds of $4.0 million (net approx. $3.1 million) and issued shares under an equity purchase agreement that was subsequently terminated on August 13, 2025. Debt and credit facilities remain significant, including a revolving line of credit balance of $3.98 million and seller notes with $5.0 million classified as current. Intangible assets and goodwill are material on the balance sheet (~$19.2 million and $16.2 million, respectively). The filing also discloses a customer concentration risk (~15% of revenue) and elevated stock-based compensation and restricted-share programs.
FAQ
What is the current stock price of Wellgistics Health (WGRX)?
What is the market cap of Wellgistics Health (WGRX)?
